Idorsia Ltd. (IDRSF)
7.25
0.00 (0.00%)
USD |
OTCM |
Aug 24, 16:00
Idorsia Enterprise Value : 3.462B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 3.462B |
| August 21, 2026 | 3.462B |
| August 20, 2026 | 3.478B |
| August 19, 2026 | 3.478B |
| August 18, 2026 | 3.478B |
| August 17, 2026 | 3.593B |
| August 14, 2026 | 3.593B |
| August 13, 2026 | 3.593B |
| August 12, 2026 | 3.633B |
| August 11, 2026 | 3.633B |
| August 10, 2026 | 3.383B |
| August 07, 2026 | 3.383B |
| August 06, 2026 | 3.383B |
| August 05, 2026 | 3.383B |
| August 04, 2026 | 3.383B |
| August 03, 2026 | 3.659B |
| July 31, 2026 | 3.659B |
| July 30, 2026 | 3.659B |
| July 29, 2026 | 3.659B |
| July 28, 2026 | 3.659B |
| July 27, 2026 | 3.709B |
| July 24, 2026 | 3.554B |
| July 23, 2026 | 3.554B |
| July 22, 2026 | 3.554B |
| July 21, 2026 | 3.554B |
| Date | Value |
|---|---|
| July 20, 2026 | 3.462B |
| July 17, 2026 | 3.462B |
| July 16, 2026 | 3.659B |
| July 15, 2026 | 3.659B |
| July 14, 2026 | 3.659B |
| July 13, 2026 | 3.659B |
| July 10, 2026 | 3.659B |
| July 09, 2026 | 3.659B |
| July 08, 2026 | 3.659B |
| July 07, 2026 | 3.659B |
| July 06, 2026 | 3.659B |
| July 02, 2026 | 3.501B |
| July 01, 2026 | 3.501B |
| June 30, 2026 | 3.501B |
| June 29, 2026 | 3.431B |
| June 26, 2026 | 3.431B |
| June 25, 2026 | 3.431B |
| June 24, 2026 | 3.393B |
| June 23, 2026 | 3.330B |
| June 22, 2026 | 3.330B |
| June 18, 2026 | 3.457B |
| June 17, 2026 | 3.012B |
| June 16, 2026 | 3.012B |
| June 15, 2026 | 3.012B |
| June 12, 2026 | 3.012B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 35.54B |
| AC Immune SA | 172.21M |
| CRISPR Therapeutics AG | 3.936B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -135.44M |
| Revenue (Quarterly) | 66.88M |
| Total Expenses (Quarterly) | 202.32M |
| EPS Diluted (Quarterly) | -0.5293 |
| Gross Profit Margin (Quarterly) | 72.13% |
| Profit Margin (Quarterly) | -202.5% |
| Earnings Yield | -22.77% |
| Normalized Earnings Yield | -18.19 |